ZA200404549B - Drivatives of phenoxy-N-[4-(1,1-dioxoisothiazolidin-2-yl)phenyl]-valeramide and other compounds as inhibitors of coagulation factor Xa for treatment of thromboembolic diseases and tumuors. - Google Patents
Drivatives of phenoxy-N-[4-(1,1-dioxoisothiazolidin-2-yl)phenyl]-valeramide and other compounds as inhibitors of coagulation factor Xa for treatment of thromboembolic diseases and tumuors. Download PDFInfo
- Publication number
- ZA200404549B ZA200404549B ZA200404549A ZA200404549A ZA200404549B ZA 200404549 B ZA200404549 B ZA 200404549B ZA 200404549 A ZA200404549 A ZA 200404549A ZA 200404549 A ZA200404549 A ZA 200404549A ZA 200404549 B ZA200404549 B ZA 200404549B
- Authority
- ZA
- South Africa
- Prior art keywords
- phenyl
- hal
- monosubstituted
- solvates
- ratios
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 86
- 238000011282 treatment Methods 0.000 title claims description 21
- 108010074860 Factor Xa Proteins 0.000 title claims description 15
- 239000003112 inhibitor Substances 0.000 title claims description 9
- 208000001435 Thromboembolism Diseases 0.000 title description 5
- CLYGGPMBSPMJPL-UHFFFAOYSA-N N-[4-(1,1-dioxo-1,2-thiazolidin-2-yl)phenyl]-2-phenoxypentanamide Chemical compound O(C1=CC=CC=C1)C(C(=O)NC1=CC=C(C=C1)N1S(CCC1)(=O)=O)CCC CLYGGPMBSPMJPL-UHFFFAOYSA-N 0.000 title 1
- -1 piperidine-1,2-diyl Chemical group 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 49
- 239000012453 solvate Substances 0.000 claims description 36
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 23
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 20
- 125000002950 monocyclic group Chemical group 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 18
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 16
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 15
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 14
- 125000004434 sulfur atom Chemical group 0.000 claims description 14
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 13
- 208000007536 Thrombosis Diseases 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000002399 angioplasty Methods 0.000 claims description 9
- 125000002619 bicyclic group Chemical group 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 9
- 206010002383 Angina Pectoris Diseases 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 206010022562 Intermittent claudication Diseases 0.000 claims description 8
- 206010027476 Metastases Diseases 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 8
- 235000010290 biphenyl Nutrition 0.000 claims description 8
- 239000004305 biphenyl Substances 0.000 claims description 8
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 208000037803 restenosis Diseases 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 7
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 7
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 7
- 208000019695 Migraine disease Diseases 0.000 claims description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 7
- 239000003114 blood coagulation factor Substances 0.000 claims description 7
- 125000001624 naphthyl group Chemical group 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229950001902 dimevamide Drugs 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 238000003797 solvolysis reaction Methods 0.000 claims description 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 3
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 2
- 150000003857 carboxamides Chemical class 0.000 claims 2
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 claims 2
- INEZVYKZWCBVIE-UHFFFAOYSA-N 2-(1-aminoisoquinolin-7-yl)oxy-n-[4-(1,1-dioxo-1,2-thiazolidin-2-yl)-3-methylphenyl]-4-methylpentanamide Chemical compound C=1C=C2C=CN=C(N)C2=CC=1OC(CC(C)C)C(=O)NC(C=C1C)=CC=C1N1CCCS1(=O)=O INEZVYKZWCBVIE-UHFFFAOYSA-N 0.000 claims 1
- ZRGBYKXECUAVKG-UHFFFAOYSA-N 2-(1-aminoisoquinolin-7-yl)oxy-n-[4-(1,1-dioxo-1,2-thiazolidin-2-yl)phenyl]-3-phenylpropanamide Chemical compound C1=C2C(N)=NC=CC2=CC=C1OC(C(=O)NC=1C=CC(=CC=1)N1S(CCC1)(=O)=O)CC1=CC=CC=C1 ZRGBYKXECUAVKG-UHFFFAOYSA-N 0.000 claims 1
- NKNDYOBDQPKWQU-UHFFFAOYSA-N 2-[3-(aminomethyl)anilino]-n-[4-(1,1-dioxo-1,2-thiazolidin-2-yl)-3-(trifluoromethyl)phenyl]-2-(2-fluorophenyl)acetamide Chemical compound NCC1=CC=CC(NC(C(=O)NC=2C=C(C(N3S(CCC3)(=O)=O)=CC=2)C(F)(F)F)C=2C(=CC=CC=2)F)=C1 NKNDYOBDQPKWQU-UHFFFAOYSA-N 0.000 claims 1
- SENGKWBHEKBOFL-UHFFFAOYSA-N 2-[3-(aminomethyl)anilino]-n-[4-(1,1-dioxo-1,2-thiazolidin-2-yl)-3-(trifluoromethyl)phenyl]-2-phenylacetamide Chemical compound NCC1=CC=CC(NC(C(=O)NC=2C=C(C(N3S(CCC3)(=O)=O)=CC=2)C(F)(F)F)C=2C=CC=CC=2)=C1 SENGKWBHEKBOFL-UHFFFAOYSA-N 0.000 claims 1
- CBIUPDNWVNQXOL-UHFFFAOYSA-N 2-[3-(aminomethyl)anilino]-n-[4-(1,1-dioxo-1,2-thiazolidin-2-yl)-3-methylphenyl]-3-phenylpropanamide Chemical compound C=1C=C(N2S(CCC2)(=O)=O)C(C)=CC=1NC(=O)C(NC=1C=C(CN)C=CC=1)CC1=CC=CC=C1 CBIUPDNWVNQXOL-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000000543 intermediate Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 description 10
- 108090000190 Thrombin Proteins 0.000 description 8
- 229960004072 thrombin Drugs 0.000 description 8
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000002785 anti-thrombosis Effects 0.000 description 5
- 229940127219 anticoagulant drug Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 108010048049 Factor IXa Proteins 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 230000014508 negative regulation of coagulation Effects 0.000 description 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- PVPBBTJXIKFICP-UHFFFAOYSA-N (7-aminophenothiazin-3-ylidene)azanium;chloride Chemical compound [Cl-].C1=CC(=[NH2+])C=C2SC3=CC(N)=CC=C3N=C21 PVPBBTJXIKFICP-UHFFFAOYSA-N 0.000 description 1
- 125000005919 1,2,2-trimethylpropyl group Chemical group 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- 125000004539 5-benzimidazolyl group Chemical group N1=CNC2=C1C=CC(=C2)* 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000021910 Cerebral Arterial disease Diseases 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- ZARRGTFQFQYQND-UHFFFAOYSA-N N-[[(butylsulfonylamino)-methylsulfamoyl]-(ethylsulfonylamino)methyl]propane-1-sulfonamide Chemical group C(C)S(=O)(=O)NC(S(=O)(=O)N(C)NS(=O)(=O)CCCC)NS(=O)(=O)CCC ZARRGTFQFQYQND-UHFFFAOYSA-N 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- FSEXLNMNADBYJU-UHFFFAOYSA-N alpha-Phenylquinoline Natural products C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=N1 FSEXLNMNADBYJU-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000004784 molecular pathogenesis Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- UHNHTTIUNATJKL-UHFFFAOYSA-N n-methylmethanesulfonamide Chemical group CNS(C)(=O)=O UHNHTTIUNATJKL-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940021317 other blood product in atc Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10155075A DE10155075A1 (de) | 2001-11-09 | 2001-11-09 | Cyclische Sulfonamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200404549B true ZA200404549B (en) | 2005-02-04 |
Family
ID=7705183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200404549A ZA200404549B (en) | 2001-11-09 | 2004-06-08 | Drivatives of phenoxy-N-[4-(1,1-dioxoisothiazolidin-2-yl)phenyl]-valeramide and other compounds as inhibitors of coagulation factor Xa for treatment of thromboembolic diseases and tumuors. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7199133B2 (es) |
| EP (1) | EP1441726B1 (es) |
| JP (1) | JP4447909B2 (es) |
| KR (1) | KR20050035165A (es) |
| CN (1) | CN1582148A (es) |
| AR (1) | AR037342A1 (es) |
| AT (1) | ATE348611T1 (es) |
| AU (1) | AU2002363366B2 (es) |
| BR (1) | BR0213680A (es) |
| CA (1) | CA2465713A1 (es) |
| DE (2) | DE10155075A1 (es) |
| DK (1) | DK1441726T3 (es) |
| ES (1) | ES2277623T3 (es) |
| HU (1) | HUP0401983A2 (es) |
| MX (1) | MXPA04004307A (es) |
| MY (1) | MY134079A (es) |
| PL (1) | PL369737A1 (es) |
| PT (1) | PT1441726E (es) |
| RU (1) | RU2301228C2 (es) |
| WO (1) | WO2003039543A1 (es) |
| ZA (1) | ZA200404549B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2416384A1 (en) * | 2000-07-17 | 2003-01-16 | Takeda Chemical Industries, Ltd. | Sulfone derivatives, their production and use |
| US20040152741A1 (en) * | 2002-09-09 | 2004-08-05 | Nps Allelix Corporation | Arylglycine derivatives and their use as glycine transport inhibitors |
| CA2507026A1 (en) * | 2002-11-22 | 2004-06-10 | Takeda Pharmaceutical Company Limited | Imidazole derivatives, their production and use |
| US7371743B2 (en) | 2004-02-28 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Carboxylic acid amides, the preparation thereof and their use as medicaments |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| DE102004054847A1 (de) * | 2004-11-13 | 2006-05-24 | Sanofi-Aventis Deutschland Gmbh | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| KR101009594B1 (ko) * | 2007-05-09 | 2011-01-20 | 주식회사 레고켐 바이오사이언스 | Ｐ4 위치에 사이클릭 아미딘을 가지는 ＦＸａ 저해제, 이의유도체, 제조방법 및 이를 함유하는 의약 조성물 |
| SG185263A1 (en) * | 2007-09-28 | 2012-11-29 | Portola Pharm Inc | Antidotes for factor xa inhibitors and methods of using the same |
| BR112015010186A2 (pt) * | 2012-11-05 | 2017-07-11 | Nant Holdings Ip Llc | sulfonamida cíclica contendo derivados como inibidores da via de sinalização de hedgehog |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5300523A (en) * | 1988-07-28 | 1994-04-05 | Bayer Aktiengesellschaft | Substituted aminomethyltetralins and their heterocyclic analogues |
| DE3901814A1 (de) * | 1988-07-28 | 1990-02-01 | Bayer Ag | Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga |
| AU4224993A (en) * | 1992-08-19 | 1994-03-15 | Pfizer Inc. | Substituted benzylamino nitrogen containing non-aromatic heterocycles |
| US5550139A (en) * | 1994-01-03 | 1996-08-27 | The Wichita State University | Serine protease inhibitors |
| GB9715895D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
| AR016133A1 (es) * | 1997-07-31 | 2001-06-20 | Wyeth Corp | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria |
| US6489300B1 (en) * | 1997-07-31 | 2002-12-03 | Eugene D. Thorsett | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| DE19751949A1 (de) * | 1997-11-24 | 1999-05-27 | Bayer Ag | Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration |
| DE19754573A1 (de) * | 1997-12-09 | 1999-06-10 | Bayer Ag | Pharmazeutische Zusammensetzung zur Behandlung von Schlaganfall und Schädel-Hirn-Trauma |
| DE19804085A1 (de) | 1998-02-03 | 1999-08-05 | Boehringer Ingelheim Pharma | 5-Gliedrige heterocyclische kondensierte Benzoderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| US6114532A (en) * | 1998-02-03 | 2000-09-05 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals |
| PT1163237E (pt) * | 1999-03-17 | 2004-08-31 | Astrazeneca Ab | Derivados de amida |
| WO2001055146A1 (en) * | 2000-01-29 | 2001-08-02 | Lg Chem Investment Ltd. | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF |
| KR100423899B1 (ko) * | 2000-05-10 | 2004-03-24 | 주식회사 엘지생명과학 | 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸 |
| AU1152702A (en) * | 2000-10-12 | 2002-04-22 | Merck & Co Inc | Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| US6488154B1 (en) * | 2000-10-16 | 2002-12-03 | Ming-Chuan Yeh | Chip tray |
-
2001
- 2001-11-09 DE DE10155075A patent/DE10155075A1/de not_active Withdrawn
-
2002
- 2002-10-10 DK DK02802623T patent/DK1441726T3/da active
- 2002-10-10 JP JP2003541834A patent/JP4447909B2/ja not_active Expired - Fee Related
- 2002-10-10 WO PCT/EP2002/011349 patent/WO2003039543A1/de active IP Right Grant
- 2002-10-10 RU RU2004117594/04A patent/RU2301228C2/ru not_active IP Right Cessation
- 2002-10-10 KR KR1020047005508A patent/KR20050035165A/ko not_active Application Discontinuation
- 2002-10-10 AU AU2002363366A patent/AU2002363366B2/en not_active Ceased
- 2002-10-10 AT AT02802623T patent/ATE348611T1/de not_active IP Right Cessation
- 2002-10-10 CN CNA028219198A patent/CN1582148A/zh active Pending
- 2002-10-10 PT PT02802623T patent/PT1441726E/pt unknown
- 2002-10-10 EP EP02802623A patent/EP1441726B1/de not_active Expired - Lifetime
- 2002-10-10 PL PL02369737A patent/PL369737A1/xx unknown
- 2002-10-10 CA CA002465713A patent/CA2465713A1/en not_active Abandoned
- 2002-10-10 MX MXPA04004307A patent/MXPA04004307A/es unknown
- 2002-10-10 HU HU0401983A patent/HUP0401983A2/hu unknown
- 2002-10-10 ES ES02802623T patent/ES2277623T3/es not_active Expired - Lifetime
- 2002-10-10 BR BR0213680-5A patent/BR0213680A/pt not_active IP Right Cessation
- 2002-10-10 DE DE50209031T patent/DE50209031D1/de not_active Expired - Lifetime
- 2002-10-10 US US10/495,254 patent/US7199133B2/en not_active Expired - Fee Related
- 2002-11-06 MY MYPI20024148A patent/MY134079A/en unknown
- 2002-11-08 AR ARP020104288A patent/AR037342A1/es unknown
-
2004
- 2004-06-08 ZA ZA200404549A patent/ZA200404549B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1441726B1 (de) | 2006-12-20 |
| US20040254175A1 (en) | 2004-12-16 |
| WO2003039543A1 (de) | 2003-05-15 |
| ATE348611T1 (de) | 2007-01-15 |
| RU2004117594A (ru) | 2006-01-10 |
| MY134079A (en) | 2007-11-30 |
| CN1582148A (zh) | 2005-02-16 |
| AU2002363366B2 (en) | 2007-11-22 |
| US7199133B2 (en) | 2007-04-03 |
| PT1441726E (pt) | 2007-03-30 |
| DK1441726T3 (da) | 2007-04-10 |
| EP1441726A1 (de) | 2004-08-04 |
| JP4447909B2 (ja) | 2010-04-07 |
| KR20050035165A (ko) | 2005-04-15 |
| DE50209031D1 (de) | 2007-02-01 |
| JP2005522412A (ja) | 2005-07-28 |
| MXPA04004307A (es) | 2004-08-11 |
| DE10155075A1 (de) | 2003-05-22 |
| AR037342A1 (es) | 2004-11-03 |
| ES2277623T3 (es) | 2007-07-16 |
| PL369737A1 (en) | 2005-05-02 |
| BR0213680A (pt) | 2004-10-26 |
| RU2301228C2 (ru) | 2007-06-20 |
| CA2465713A1 (en) | 2003-05-15 |
| HUP0401983A2 (hu) | 2005-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7273867B2 (en) | Phenyl derivatives | |
| ZA200305455B (en) | Carboxylic acid amide derivatives and their use in the treatment of thromboembolic diseases and tumours. | |
| AU2002227993A1 (en) | Phenyl derivatives | |
| ZA200308028B (en) | Phenyl derivatives 3. | |
| US20050203127A1 (en) | 2-(Phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses | |
| ZA200404549B (en) | Drivatives of phenoxy-N-[4-(1,1-dioxoisothiazolidin-2-yl)phenyl]-valeramide and other compounds as inhibitors of coagulation factor Xa for treatment of thromboembolic diseases and tumuors. | |
| ZA200506730B (en) | Carboxamide derivatives and their use as factor XA inhibitors | |
| ZA200308669B (en) | Oxalic acid derivatives. | |
| ZA200308060B (en) | Biurethane derivatives. | |
| US20050176760A1 (en) | N-'4-(2-imino-pyrrolidin-1-yl)phenyl!-acetamide and corresponding piperidine derivatives as factor xa inhibitors for the treatment of thrombo-embolic diseases | |
| US7902223B2 (en) | Phenyl derivatives as factor XA inhibitors | |
| US20030176465A1 (en) | Cyclic amino acid derivatives | |
| ZA200407903B (en) | Semicarbazide derivatives and their use as antithrombotics. | |
| ZA200301471B (en) | N-substituted 1-amino-1,1-dialkylcarboxylic acid derivatives. | |
| US20040092517A1 (en) | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | |
| AU2002250878A1 (en) | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | |
| ZA200400486B (en) | Carbohydrate derivatives. | |
| ZA200301638B (en) | Urethane derivatives. |